Purdue Pharma in Talks to Resolve Opioid Cases Through Bankruptcy

Addiction experts are in wide agreement on the most effective way to help opioid addicts: Medication-assisted treatment. But most inpatient rehab facilities in the U.S. don’t offer this option. WSJ’s Jason Bellini reports on why the medication option is controversial, and in many places, hard to come by. Image: Ryno Eksteen and Thomas Williams

OxyContin maker Purdue Pharma LP and its owners, the Sackler family, are in talks with state and local governments to resolve more than 2,000 opioid cases in a deal valued at between $10 billion and $12 billion, according to people familiar with the matter.

The discussions, part of a mediation to end the mounting litigation that seeks to blame Purdue for fueling the opioid crisis, have been ongoing for more than a year and remain in flux, the people said.